Two cases of fetal malformation after exposure to low dose warfarin sodium tablets in early pregnancy

doi:10.19803/j.1672-8629.20230074

Abstract

Abstract: Objective To investigate the influencing factors and pharmacogenetic effects of fetal malformation caused by maternal exposure to low-dose warfarin sodium tablets during early pregnancy. Methods Two cases of fetal cleft lips and palates as well as short nasal bone development due to exposure to low-dose warfarin sodium tablets(<5 mg·d^-1) during early pregnancy for anticoagulation after mechanical valve replacement were reported. The possible drug correlations and teratogenic molecular mechanism between fetal malformation and low-dose warfarin were discussed based on related literature. Results and Conclusion In Chinese populations, low-dose warfarin exposure(<5 mg·d^-1) in early pregnancy can increase the risk of fetal oral-facial malformation, and its teratogenic mechanism may be correlated with the maternal warfarin dose, exposure time window and individual differences. Literature suggests that inter-individual CYP2C9, VKORC1 gene polymorphisms and AYL Sulfatase E gene mutations may also play a key role, which deserves clinical attention.

Key words: warfarin sodium tablets, pregnancy, low-dose, cleft lip and palate, nasal bone hypoplasia, adverse drug reaction

CLC Number:

R972
R994.11

YANG Caihua, YANG Longna, LI Xiaobo. Two cases of fetal malformation after exposure to low dose warfarin sodium tablets in early pregnancy[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1286-1289.

References

[1] Obstetrics Group, Society of Obstetrics and Gynecology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pregnancy complicated with heart disease[J]. Chinese Journal of Obstetrics and Gynecology(中华妇产科杂志), 2016, 51(6): 401-409.
[2] Orion Corporation Orion Pharma. Drug lable-warfarin sodium tablets[EB/OL]. (2017-09-22)[2023-02-02]. https://drugs.dxy.cn/drug/WFWYwP0hTQnV1vW7sPHM8w==.
[3] REGITZ-ZAGROSEK V, ROOS-HESSELINK JW, BAUERSACHS J, et al.2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy[J]. Kardiol Pol, 2019, 77(3): 245-326.
[4] HOLBROOK A, SCHULMAN S, WITT DM, et al.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl): e152-e184.
[5] BASU S, AGGARWAL P, KAKANI N, et al.Low-dose maternal warfarin intake resulting in fetal warfarin syndrome: in search for a safe anticoagulant regimen during pregnancy[J]. Birth Defects Res A Clin Mol Teratol, 2016,106(2): 142-147.
[6] SOUSA RA, BARREIRA R, SANTOS E. Low-dose warfarin maternal anticoagulation and fetal warfarin syndrome[J]. BMJ Case Rep, 2018, 7: bcr2017223159.
[7] ARIF OK.Optic nerve dysfunction in a child following low-dose maternal warfarin exposure[J]. Ophthalmic Genet, 2007, 28(3): 183-184.
[8] Wolters Kluwer.Uptodate[EB/OL].[2023-02-01].https://www.uptodate.cn/home.
[9] Center for Drug Reevaluation. Provisions for Adverse Drug Reaction Reporting and Monitoring(《药品不良反应报告和监测管理办法》培训教材)[M]. Beijing: China Medical Science Press, 2012.
[10] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[11] MOORE KL, PERSAUD V, TORCHIA MG, et al.Torchia: The Developing Human. Clinically Oriented Embryology[M]. 11th ed, Philadelphia: Elsevier, 2020: 516.
[12] XU Z, FAN J, LUO X, et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systematic review and Meta-analysis[J]. Can J Cardiol, 2016, 32(10): 1248.e1-1248.e9.
[13] COTRUFO M, DE FEO M, DE SANTO LS, et al.Risk of warfarin during pregnancy with mechanical valve prostheses[J]. Obstet Gynecol, 2002, 99(1): 35-40.
[14] DONG L, SHI YK, XU JP, et al.Registration and follow-up study of multi center low intensity anticoagulation therapy after cardiac valve surgery in China[J]. Chinese Journal of medicine, 2016, 96(19): 1489-1494.
[15] DANG MT, HAMBLETON J, KAYSER SR.The influence of ethnicity on warfarin dosage requirement[J]. Ann Pharmacother, 2005, 39(6): 1008-1012.
[16] XUE Q, LI N, CHU H, et al.Prospective study of anticoagulant therapy in pregnancy after mechanical aortic valve replacement[J]. International journal of cardiovascular disease(国际心血管病杂志), 2018, 45(1): 54-57.
[17] SUWANAWIBOON B, ROTCHANAPANYA W, MAHAPROM K.The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial[J]. Hematology, 2022, 27(1): 95-104.
[18] WANG LY.Effects of MDR1 gene polymorphism on warfarin stable dose in Han Chinese in East China[D]. Shanghai: PLA Navy Military Medical University, 2018.
[19] RIEDER MJ, REINER AP, GAGE BF, et al.Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose[J]. N Engl J Med, 2005, 352(22): 2285-2293.
[20] PAULI RM, LIAN JB, MOSHER DF, et al.Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives[J]. Am J Hum Genet, 1987, 41(4): 566-583.
[21] JOHNSON JA, CAUDLE KE, GONG L, et al.Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics guided warfarin dosing: 2017 Update[J]. Clin Pharmacol Ther, 2017, 102(3): 397-404.